Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Pfizer's Rheumatoid Arthritis Drug Xeljanz Gets Approval In Japan

Pharmaceutical giant Pfizer Inc. (PFE: Quote) Monday said the Japanese Ministry of Health, Labor and Welfare has approved Xeljanz for the treatment of adults with rheumatoid arthritis or RA who have had an inadequate response to existing therapies. The company added saying the drug may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug, such as methotrexate.

Xeljanz is expected to be initially made available in Japan to medical institutions participating in an all-patient surveillance program. The drug will be commercially available in Japan after the National Health Insurance listing and will be co-promoted in Japan by Pfizer and Takeda Pharmaceutical Company Limited.

The approval of Xeljanz in Japan is supported by a multi-study, global clinical development program, which evaluated the drug in approximately 5,000 patients across various RA patient populations.

Click here to receive FREE breaking news email alerts for Pfizer Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Republicans have not found much to like about President Barack Obama's nearly six years in office, but the results of a new Washington Post-ABC News poll show that a vast majority support the president's decision to launch airstrikes in Iraq. While stocks have largely maintained a positive bias over the course of the trading day on Thursday, the major averages are turning in a mixed performance in mid-day trading. The S&P 500 has reached a new record intraday high and the Dow has climbed back above 17,000, while the tech-heavy Nasdaq is posting a modest loss. Suggesting that the economy is gaining traction, the Conference Board released a report on Thursday showing a bigger than expected increase by its index of leading U.S. economic indicators in July.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.